Description

Meridia® 15 mg (Sibutramine HCl Monohydrate)

Brand: Bariatrics (Abbott)
Category: Centrally acting monoamine-reuptake modulator (SNRI) – Research chemical
Content: 30 capsules · 15 mg sibutramine HCl monohydrate per capsule
Price: €29
Manufactured in: Europe
Research Notice: FOR RESEARCH USE ONLY. Not for human or veterinary use.

🧪 Product Overview

Meridia® 15 mg contains sibutramine hydrochloride monohydrate, a centrally acting
serotonin–norepinephrine reuptake inhibitor (SNRI) historically indicated for weight management
until its withdrawal following the SCOUT cardiovascular-outcomes trial.
It is now used exclusively as a laboratory/analytical reference compound for studies on
monoamine signaling, appetite regulation, toxicology, and forensic method development.

Sibutramine increases synaptic concentrations of serotonin (5-HT) and
norepinephrine (NE) by blocking their reuptake transporters. Its active metabolites
(M1/M2) are chiefly responsible for appetite-suppression pathways and sympathetic activation.

✅ Key Research Highlights

Monoamine reuptake inhibition:
Blocks SERT and NET (± DAT) → ↑ 5-HT/NE levels → enhanced satiety signaling.
Documented extensively in DrugBank and PubChem entries.

Historical pharmacotherapy:
Originally approved for obesity management; later withdrawn (EU/US, 2010) due to increased risk of
non-fatal MI and stroke in high-risk cardiovascular patients (SCOUT trial – NEJM).

Anti-doping relevance:
Classified under WADA Stimulants (in-competition). Athletes must confirm status via Global DRO.

Laboratory value:
Used in metabolic, toxicological, chromatographic, and receptor-transporter profiling workflows.

🧬 Mechanism of Action (Simplified)

Sibutramine is metabolized into two active metabolites (M1 & M2) which:

• Block serotonin (SERT) and norepinephrine (NET) transporters
• Increase synaptic monoamines → enhanced satiety and reduced caloric intake
• Produce mild sympathetic activation → increased HR/BP in clinical history

This profile supports its use in monoamine and appetite-regulation research models.

📊 Scientific Data Table

📚 Research Background

• SCOUT Trial (NEJM): Increased non-fatal MI and stroke in high-risk cardiovascular groups → regulatory withdrawal.
• Mechanistic relevance: Appetite suppression linked to SERT/NET inhibition and downstream hypothalamic pathways.
• Toxicology interest: Cardiovascular, serotonergic, and sympathomimetic components evaluated in controlled studies.

⚠️ Documented Risks (Historical Medicinal Use)

• ↑ Heart rate and blood pressure
• Increased risk of non-fatal MI and stroke (SCOUT)
• Insomnia, dry mouth, headache, constipation
• Possible serotonin-related interactions (SSRIs/MAOIs)

🧯 Compliance & Legal Status

Regulation: Suspended/withdrawn in EU/US (2010). Not marketed as a medicinal product on this site.
Research-only: Supplied strictly for laboratory/analytical use.
Sport: Listed under WADA Stimulants (Prohibited In-Competition).
Researchers and athletes must verify local regulations and anti-doping rules.

📌 Important Notice

This compound is for laboratory research only.
Not for human consumption, therapeutic use, or veterinary application.
Users are responsible for compliance with local laws, regulations, and safety protocols.